Emerging leader in chronic pain and neurological medical devices selects Global 2.0 to manage its medical device approvals and submissions worldwide.
Framingham, MA, June 9, 2005 – clinivation, Inc. announced today that ANS, Advanced Neuromodulation Systems, Inc. (NASDAQ NM: ANSI) has selected clinivation Global™ 2.0 software.
“ANS-medical is clearly an emerging leader in the development of solutions for chronic pain and other neurological conditions, and we are delighted they have selected clinivation Global 2.0 to help them build and track their medical device approvals and submissions worldwide,” said Joseph Kozikowski, M.D., clinivation’s Founder, Chairman, and Chief Executive Officer.
Clinivation Global 2.0 software enables medical device companies to sell more products to more countries faster and easier than ever before. Global 2.0 is the first complete solution targeted at automating the business processes for medical device approvals worldwide.
About Advanced Neuromodulation Systems, Inc.
Advanced Neuromodulation Systems designs, develops, manufactures and markets implantable systems used to manage chronic intractable pain and other disorders of the central nervous system. Fortune magazine recently ranked ANS as the 8th fastest growing small company in its annual list of the Top 200 Fastest Growing Small Companies in the United States. Forbes magazine recently recognized ANS as one of America’s 200 Best Small Companies. Frost & Sullivan, an international strategic market research firm, also recently presented ANS with its Product Innovation Award, recognizing ANS as the technology innovation leader in the neurostimulation market and ANS’ Genesis® Implantable Pulse Generator system as the most advanced fully implantable spinal cord stimulator on the market.
For more information about ANS, visit the company website at www.ans-medical.com
